Patrick Reid, president and CEO of PeptiDream Inc Photo: REUTERS/Rocky Swift
executive impact

Biotech-for-hire PeptiDream charts new path and becomes short target

By Rocky Swift

The requested article has expired, and is no longer available. Any related articles, and user comments are shown below.

© Thomson Reuters 2019.

©2020 GPlusMedia Inc.

Login to comment

PeptiDream is based on some genius ideas from Prof. Suga, and in the scientific world there is a lot of hope it will bring some great breakthrough drugs. Everything else is parazite analysts' speculations, who don't have any ideas on their own and just try to cash in

1 ( +1 / -0 )

I intend to agree with timeon. The technology behind PeptiDream is very solid and may well lead to a better class of drugs for a wide range of diseases.

At the same time, the stock may well be overvalued, due to the bubbly nature of Japan, where human beings are turned into deities, only to fall, in the public's eyes, back to reality.

All said and done, the publicity is probably good for them!

0 ( +0 / -0 )

Login to leave a comment

Facebook users

Use your Facebook account to login or register with JapanToday. By doing so, you will also receive an email inviting you to receive our news alerts.

Facebook Connect

Login with your JapanToday account

User registration

Articles, Offers & Useful Resources

A mix of what's trending on our other sites